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PAK2 is an effector of TSC1/2 
signaling independent of mTOR 
and a potential therapeutic target 
for Tuberous Sclerosis Complex
Maria M. Alves1,†, Gwenny M. Fuhler1, Karla C.S. Queiroz2, Jetse Scholma1, Susan Goorden3, 
Jasper Anink4, C. Arnold Spek2, Marianne Hoogeveen-Westerveld5, Marco J. Bruno1, 
Mark Nellist5, Ype Elgersma3, Eleonora Aronica4,6 & Maikel P. Peppelenbosch1
Tuberous sclerosis complex (TSC) is caused by inactivating mutations in either TSC1 or TSC2 and is 
characterized by uncontrolled mTORC1 activation. Drugs that reduce mTOR activity are only partially 
successful in the treatment of TSC, suggesting that mTOR-independent pathways play a role in 
disease development. Here, kinome profiles of wild-type and Tsc2−/− mouse embryonic fibroblasts 
(MEFs) were generated, revealing a prominent role for PAK2 in signal transduction downstream of 
TSC1/2. Further investigation showed that the effect of the TSC1/2 complex on PAK2 is mediated 
through RHEB, but is independent of mTOR and p21RAC. We also demonstrated that PAK2 over-
activation is likely responsible for the migratory and cell cycle abnormalities observed in Tsc2−/− 
MEFs. Finally, we detected high levels of PAK2 activation in giant cells in the brains of TSC patients. 
These results show that PAK2 is a direct effector of TSC1-TSC2-RHEB signaling and a new target for 
rational drug therapy in TSC.
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by the pres-
ence of benign tumours in the brain and in other vital organs such as the kidneys, heart, eyes, lungs, and 
skin, and is associated with severe neurological and behavioral symptoms. Up to 90% of patients suffer 
from epilepsy, and almost 50% have intellectual disabilities1. TSC is caused by a heterozygous mutation 
in either TSC12,3 or TSC24,5 which encode for hamartin (TSC1) and tuberin (TSC2), respectively6. These 
two proteins interact with each other7 to form a functional heterodimeric complex that controls different 
aspects of cellular metabolism by its GTPase activating function towards the Ras homolog enriched in 
brain protein (RHEB)8. In a normal situation, the TSC1-TSC2 complex inactivates RHEB by stimulating 
the conversion of RHEB-GTP to RHEB-GDP, which subsequently downregulates the mammallian target 
of rapamycin (mTOR) signaling pathway9. In the presence of a mutation in either TSC1 or TSC2, the 
TSC1-TSC2 complex is unable to form and RHEB is kept in a permanently active, GTP-bound state, 
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leading to constitutive activation of the mTOR pathway and, as a consequence, to uncontrolled cell 
growth. The importance of mTOR signaling downstream of the TSC genes is further illustrated by the 
observation that upregulation of TSC1 following ischaemia induces protective autophagia via inhibition 
of the mTOR pathway and can protect neurons from ischaemia-induced cell death10.
mTOR is an important regulator of cellular metabolism and has multiple downstream targets includ-
ing p70S6 kinase and the eukaryotic initiation factor 4E (eIF4E)-binding proteins 1 and 2 (4E-BP1 and 
4E-BP2)11. Various molecules are potent inhibitors of mTOR and are used clinically to combat disease 
characterised by excessive mTOR activity, including TSC. Rapamycin and its analogues such as sirolimus 
and everolimus, play a prominent role in this respect. Rapamycin is a macrolide antibiotic that blocks 
mTOR signaling by forming an inhibitory complex with the cytosolic FK-binding protein-12 (FKBP-
12)12. The Rapamycin-FKBP12 complex directly binds and inhibits mTOR when present in a protein 
complex consisting of mTOR, Raptor, LST8, PRAS and DEPTOR, together known as mTORC1, but not 
when present in the protein complex mTORC2 (consisting of mTOR, Rictor, LST8, mSIN1, DEPTOR and 
Protor). mTORC1 inhibition by rapamycin is now firmly established as a therapeutic option in various dis-
eases, especially transplantation medicine and various forms of cancer. Indeed, in two prospective studies 
sirolimus proved to be safe and effective for the treatment of TSC-associated renal angiomyolipoma13,14. 
Furthermore, everolimus substantially and significantly reduced the volume of subependymal giant cell 
astrocytomas in an open-label phase 1/2 study15, while in a larger double-blind placebo-controlled phase 
III study, it was shown to reduce tumour size and seizure frequency in a significant fraction of patients 
with TSC and associated subependymal giant cell astrocytoma16. Unfortunately, some clinical manifes-
tations of TSC, especially lung function14 and neurological symptoms, do not or only partially react 
to prolonged treatment with rapamycin analogues. Although none of the everolimus-treated patients 
progressed, only 27 (35%) of the 78 patients in the everolimus-treated group of the phase III study (ver-
sus none of the placebo group) was considered to have a response in terms of a reduction in the total 
volume of all subependymal giant cell astrocytomas16. Thus mTOR inhibition was only partially effective 
in these patients. Furthermore, TSC associated tumours are highly autophagia dependent, and as rapa-
mycin analogues are well-known to stimulate autophagia, their administration will provide a pro-survival 
stimulus that will limit their own efficacy, contributing to the partial clinical response seen for human 
angiomyolipomas and subependymal giant cell astrocytomas to mTORC1 inhibition17. Thus, alternative 
treatments are urgently called for.
The potential of prolonged rapamycin treatment to cause full mTOR inhibition is undisputed, and 
hence the failure of mTOR inhibition to counteract all manifestations of TSC indicates that mTOR may 
well not be the sole molecular mediator of the effects of TSC1/2 deficiency on the cellular phenotype14. 
Obviously, knowledge of TSC1-TSC2-regulated pathways acting in parallel with mTOR activation should 
prove exceedingly useful for designing superior clinical treatments. These considerations prompted us to 
contrast signal transduction in Tsc2−/− and wild-type mouse embryonic fibroblasts (MEFs), employing a 
peptide array approach that provides a comprehensive description of cellular kinase activity by compar-
ing the phosphorylation of 1024 different kinase substrates18,19. We have previously shown that kinome 
profiling is a powerful tool to define therapeutically interesting kinases without a priori knowledge of 
the pathways affected in different pathogeneses, since it allows the generation of complete descriptions 
of cellular kinase activity in a single experiment20,21. Our results reveal the role of TSC2 in cellular signal 
transduction and uncover a previously unrecognised action of this protein in the down regulation of 
PAK2-dependent signaling, which is independent of mTOR. Thus PAK2 constitutes a new downstream 
target of the TSC1-TSC2 complex and provides a potential novel avenue for treatment of TSC.
Results
The influence of genetic deletion of Tsc2 on the cellular kinome in MEFs. To gain insight 
into the influence of genetic deletion of Tsc2 on cellular signal transduction, we compared the kinome 
of Tsc2−/− MEFs to that of wild-type MEFs. To this end, cells were serum-starved for two hours before 
lysates were prepared, as this would be expected to increase signaling of the AMPK signal transduction 
cassette22, and thus accentuate differences in signal transduction between the two different genetic back-
grounds. Kinome profiles were then generated by incubating each cell lysate with a peptide array contain-
ing different kinase substrates in the presence of 33P-γ -ATP. Three technical replicates of two biological 
replicates of each sample were performed. The arrays incorporated substantial amounts of radioactivity 
(scans not shown). The technical quality of the profiles was good as the average Pearson product moment 
was well in excess of 0.85 between both the technical and the biological replicas for all cell types analysed 
for each condition. From a qualitative comparison, it appeared that the profile of the Tsc2−/− MEFs was 
substantially similar to the wild-type control (Supplementary figure S1). However, specific differences 
were also observed between the profiles of the two conditions (Fig. 1). As expected, the canonical effect 
of Tsc2 deletion, an upregulation of mTOR-dependent signaling, is clearly manifest: mTOR substrate 
peptides as well as substrates for p70S6 kinase, a canonical target for mTOR-dependent signal transduc-
tion12,23,24, showed increased phosphorylation when incubated with lysates obtained from Tsc2−/− MEFs 
(Fig. 1). Strikingly, AMPK activity, which negatively regulates mTOR through the TSC1-TSC2 complex25, 
is much stronger in the Tsc2−/− MEFs as well (Fig.  1), possibly reflecting a compensatory response to 
mTOR activation or a reflection of ATP depletion by over-activation of mTOR dependent signaling by 
this ADP/AMP-stimulated kinase. There is also a substantial activation of the Chk1/Chk2 cell cycle 
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Figure 1. Effect of genetic deletion of Tsc2 on signal transduction in mouse embryonic fibroblasts 
(MEFs) as determined by the phosphorylation of peptide arrays containing 1024 kinase substrates. 
Graphical impression of the results obtained, representing three technical replicas performed on two 
biological replicates. Individual results for each technical replicate were first subjected to Markov state 
analysis. (i.e. is the peptide significantly more phosphorylated than the background?) and the number of 
reactions in which this is the case (an integer between zero [in none of the 6 reactions was significant 
radioactivity incorporated into the substrate peptide] and six [in all 6 reactions significant radioactivity 
was incorporated into the substrate peptide]) were determined per peptide for each of the experimental 
conditions (listed as Markov score, Supplementary Table 1). The Markov scores obtained were collapsed on 
signal categories that provide insight into the signaling differences between the Tsc2 proficient and deficient 
cells and are expressed in grey scale (representing the number of peptides phosphorylated as a fraction of 
all peptides in that category). Note the difference in mTOR signaling, PAK signaling and Chk1/2-related 
signaling.
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checkpoint signaling network in the Tsc2−/− MEFs (Fig. 1), which may represent a p53-dependent endog-
enous feed-back mechanism activated by loss of Tsc2 to limit cell cycle progression, and may explain 
why in experimental animals genetic loss of Tsc2 enhances tumorigenesis in a p53-deficient context26. 
(Of note, while some Tsc2−/− mouse models described are p53 deficient27, the Tsc−/− MEFS used in the 
current study retain p53 expression—see supplementary Figure S2). Furthermore, this observation cor-
responds well with the fact that the AMPK activator AICAR, which acts upstream of the TSC1-TSC2 
complex11, activates the p53 pathway in a rapamycin-sensitive fashion28. Most interestingly, an up-regula-
tion of the Ras-related C3 botulinum toxin substrate 1/p21 activated kinase 2 (RAC/PAK2) pathway was 
observed in Tsc2−/− MEFs. This was evident from increased phosphorylation of substrates directly meas-
uring the activity of this kinase (Fig. 1), but also from increased activity of possible indirect effectors of 
this kinase, like p125FAK, MKK3/6 and c-Src29, in the lysates of Tsc2−/− MEFs (Supplementary table 2).
Taking into account that PAKs represent a pleiotropic family of kinases implicated in a variety of cell 
physiological effects, especially in neuronal migration30; that TSC is often considered to be a disease of 
abnormal neuronal migration31; and that PAKs are highly druggable32, these results suggest the tantalis-
ing possibility that PAKs may be involved in the development of TSC. Further investigation was initiated 
to test this notion.
Increased activity of Pak2 upon genetic inactivation of the TSC1-TSC2 complex is independ-
ent of mTor in MEFs. The kinome profiles revealed higher Pak2 enzymatic activity in MEFs geneti-
cally deficient in Tsc2. Western blot analysis of wild-type and Tsc2−/− MEFS confirmed the Tsc2-negative 
status of the Tsc2−/− MEFs, as well as the increased phosphorylation of the canonical mTor targets p70S6K 
and S6. In addition, the observed increase in Pak2 enzymatic activity in Tsc2−/− MEFs corresponded to 
an increased autophosphorylation of Pak2, detected by using an antibody against phospho-serine 20, 
an autophosphorylation site associated with the activation of this kinase (Fig.  2A). To investigate the 
mTor-dependency of Pak2 activation in this genetic model, Tsc2−/− and wild-type MEFs were incubated 
with rapamycin (Fig. 2B). As expected, rapamycin caused a strong down-regulation of p70S6K and S6 
phosphorylation and almost completely abrogated the effects of Tsc2 deficiency on this phosphoryla-
tion. Strikingly, however, Pak2 autophosphorylation measured in parallel was unaffected. Similarly, in 
Tsc1−/− MEFs, we observed a clear, rapamycin-sensitive up-regulation of p70S6K and S6 phosphoryla-
tion, whereas a strong, rapamycin-insensitive Pak2 auto-phosphorylation was seen in these cells, when 
compared to wild-type MEFs (Fig. 2C). Thus, our results show that the TSC1-TSC2 complex acts as a 
negative upstream regulator of Pak2 and that activation of this kinase following Tsc1 or Tsc2 deletion 
occurs in a mTor-independent fashion.
Rheb regulates Pak2 activation in MEFs. In canonical signal transduction, loss of the TSC1-TSC2 
complex influences cellular biochemistry through the subsequent constitutive activation of RHEB and 
mTOR. The observation that PAK2 activation as a consequence of the genetic loss of one of the compo-
nents of the TSC1-TSC2 complex is independent of mTOR raises questions as to the role of RHEB in the 
TSC1-TSC2 dependent control of PAK2 activity. To answer this question we examined Pak2 autophospho-
rylation levels in Rheb1−/− MEFs (Fig. 2D). These cells displayed very low levels of autophosphorylated 
Pak2, demonstrating that constitutive Pak2 activity requires functional Rheb. Furthermore, exogenous 
expression of a Myc-tagged version of Rheb in wild-type MEFs was sufficient to cause increased Pak2 
autophosphorylation (Fig. 2E). Finally, when Tsc2−/− MEFs were transfected with a short hairpin RNA 
targeting Rheb1, the stimulatory effect of genetic deletion of Tsc2 on Pak2 autophosphorylation was lost. 
A control short hairpin RNA did not effect either Rheb levels or Pak2 autophosphorylation (Fig.  2F). 
Taken together, these results indicate that Rheb is a major regulator of the activation status of Pak2.
Regulation of Pak2 by the TSC1/2-Rheb signaling module is independent of Rac. As the the 
canonical regulator of activity of the family of p21-activated kinases is the RAC GTPase33, we next 
investigated the activity of this protein in Tsc2−/− MEFs. Interestingly, the genetic loss of Tsc2 in MEFs 
was not accompanied by increased Rac-GTP loading (Fig. 3A). If anything Rac-GTP levels were lower 
in Tsc2−/− MEFs, hinting at the existence of Pak2 negative feedback mechanisms on Rac activation. 
Thus, we decided to investigate whether loss of Tsc2 stimulated Pak2 autophosphorylation in the pres-
ence of NSC23766, an inhibitor of RAC GDP→ GTP exchange34. Indeed treatment of wild-type MEFs 
for 30 min with 20 μ M of NSC23766 efficiently impaired GTP loading of Rac (Fig.  3B). Importantly, 
NSC23766 treatment did not markedly affect the upregulation of Pak2 autophosphorylation in Tsc2−/− 
MEFs (Fig.  3C). Furthermore, treating cells with a combination of rapamycin and NSC23766 did not 
affect Pak2 autophosphorylation (although phosphorylation of S6 was highly sensitive to this treatment). 
Hence, the TSC1/2-Rheb signaling module controls Pak2 activity in a Rac and mTOR-independent fash-
ion and represent a specific output of this signaling cascade.
Pak2 affects the migration of Tsc2−/− MEFs. Predicted consequences of exagerated PAK2 acti-
vation are cytoskeletal abnormalities and consequently impaired migratory responses. We visualised fil-
amentous actin by performing rhodamin-phalloidin stainings. Wild-type MEFs were characterised by 
relatively modest amounts of filamentous actin and highly organised stess fibers (Fig.  4A). In contrast 
Tsc2−/− MEFs exhibited robust cytoskeletal reangerangements, including the formation of numerous 
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Figure 2. Pak2 phosphorylation is resistant to rapamycin treatment and is dependent of Rheb.  
(A) Western blot analysis of wild-type and Tsc2−/− MEFs confirms the Tsc2-negative status of the Tsc2−/− MEFS 
and shows that the increased activity of Pak2 observed in the kinome profile of Tsc2−/− MEFs corresponds 
to increase autophosphorylation of Pak2 and increased phosphorylation of p70S6K and S6. (B) Treatment 
of MEFs for 1 hour with 20 nM rapamycin efficiently inhibits increased phosphorylation of p70S6K and S6 
following deletion of Tsc2, but does not affect the increase in Pak2 autophosphorylation. (C) Western blot 
analysis of wild-type and Tsc1−/− MEFs shows that loss of Tsc1 provokes autophosphorylation of Pak2 and 
phosphorylation of p70S6K and S6. The latter two events are sensitive to a 1 hour treatment of the cells with 
20 nM rapamycin, but Pak2 autophosphorylation is unaffected by this treatment. (D) Western blot analysis of 
wild-type and Rheb1−/− MEFs confirms the Rheb-negative status of the Rheb1−/− MEFS and shows decreased 
phosphorylation of Pak2, p70S6K and S6. (E) Over-expression of a Myc-tagged variant of Rheb in wild-type 
MEFs induces Pak2 activation. (F) Rheb knock down using a short hairpin RNA targeting Rheb, abrogates 
activation of Pak2 autophosphorylation in Tsc2−/− MEFs. A control hairpin shows no effect. All blots were run 
under the same conditions and analysed in a similar way.
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lamellipodium-like networks, increased disorganisation of cytoskeletal actin, the appearance of prom-
inent cortical actin structures, and the formation of many small microspikes (Fig.  4A). Furthermore, 
in scratch assays, wild-type MEFs polarised at the wound edge and migrated into the wound space, 
whereas the Tsc2−/− MEFS were much less proficient in this respect (Fig. 4B,C). In order to prove that 
the migratory defect obseved on the Tsc2−/− MEFs is induced by Pak2, we reduced Pak2 expression in 
these MEFs using a specific siRNA. We also used a non-targeting siRNA as control. We observed that in 
the Pak2 siRNA transfected MEFs cell migration was partly restored, while the control siRNA transfected 
MEFs showed no improvement (Fig.  4B,C). Efficient downmodulation of Pak2 upon siRNA treatment 
of Tsc−/− MEFs was shown by qPCR (Fig.  4D). This experiment furthermore demonstrates that the 
increased phosphorylation of Pak2 observed (Fig. 2A–C and Fig. 3C) in Tsc2−/− MEFs as compared to 
Tsc2+/+ MEFs is independent on Pak2 mRNA expression levels (lanes 1 and 2 in Fig. 4D) and thus relies 
on posttranslational modification of the Pak2 protein. In toto, these experiments show that Tsc2−/− MEFs 
demonstrate loss of migratory response which is partially dependent on Pak2.
Lesions from TSC patients show increased PAK2 autophosphorylation. Independent confirma-
tion of PAK2 activation as a downstream effect of loss of the TSC1-TSC2 complex came from experiments 
in which PAK2 autophosphorylation was investigated in the brains of TSC patients. Pathologically, TSC 
is characterized by the occurrence of multiple cortical tubers in the cerebral cortex which are thought to 
be responsible for many neuropsychiatric symptoms of TSC. Histologically, the most conspicuous feature 
of cortical tubers is the presence of giant cells, which show abnormal size and differentiation markers35. 
Strikingly, strong immunoreactivity for autophosphorylated PAK2 was observed in brain lesions from 5 
patients carrying a TSC1 or TSC2 mutation (1 TSC1: 4 TSC2). The staining was restricted to the giant cell 
compartment and was cytoplasmic, as expected based on the normal localization of this kinase (Fig. 5A). 
Double-staining for autophosporylated PAK2 and phosphorylated S6 was also performed in three lesions 
(all patients carrying TSC2 mutations). The majority of giant cells showed high levels of phosphorylated 
S6, the golden standard for positive identification of giant cells with loss of heterozygosity for TSC1 
or TSC236, and were strongly positive for PAK2 autophosphorylation (Fig.  5B). Thus PAK2 activation 
accompanies TSC loss in human disease.
Discusion
The search for new and better therapeutical targets is a constant pursuit in the treatment of different 
disorders. This is especially the case for Tuberous Sclerosis Complex (TSC), as TSC symptoms are only 
partially resolved by current therapy. In particular, the treatment of the neuropsychiatric manifestations 
Figure 3. Pak2 autophosphorylation in Tsc2−/− MEFs is independent of Rac activity. (A) The activation 
status of Rac was compared in wild-type and Tsc2−/− MEFs by pull down of Rac-GTP using recombinantly-
produced PAK-Crib proteins. Tsc2−/− MEFs are not characterised by excessive Rac activity. (B) Rac-GTP 
pull down with recombinantly-produced PAK-Crib proteins was used to investigate the effect of a 30 min 
treatment of 20 μ M NSC23766 on Rac activity. The treatment efficiently blocks GTP loading of Rac. (C) The 
effects of a 1 hour treatment with 20 nM rapamycin and a 30 min treatment with 20 μ M NSC23766 on Pak2 
autophosphorylation and S6 phosphorylation were investigated in wild-type and Tsc2−/− MEFs. Rapamycin 
efficiently inhibits S6 phosphorylation but has no effect on Pak2 autophosphorylation. NSC23766 affects 
neither Pak2 autophosphorylation nor S6 phosphorylation. The combination of rapamycin and NSC23766 
(lanes cropped from the same blot) does also not influence Pak2 phosphorylation, nor is it more effective 
on S6 phosphorylation as compared to rapamycin alone. All blots were run under the same conditions and 
analysed in a similar way.
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is as yet inadequate. So far, most attention in the search for therapeutics has been given to the mTORC1 
complex as it constitutes the canonical target of the TSC1-TSC2 complex. Here, we provide evidence that 
PAK2 signaling constitutes a second signal transduction module downstream of the TSC1-TSC2-RHEB 
signal transduction complex, whose inhibition may be potentially useful, as strong PAK2 activation 
appears to be a characteristic of human disease, at least in the brain. A proposed possible diagram as to 
how PAK2 activation might be implicated in TSC is provided in Fig. 6.
PAK2 is a serine/threonine kinase involved in cytoskeletal reorganization originally identified by its 
role in chemotactic signal transduction37, and is now well-established to be a mediator of directed cell 
migration in a variety of settings in the body38. In the context of TSC, to our knowledge no information 
has been reported hitherto, but it is well recognised that many of the psychoneurological manifestations 
of the disease involve aberrant migration of neuronal precursors39. In addition, loss of Tsc1 in mouse sub-
ventricular zone neural stem/progenitor cells leads to migration deficits that result in the development 
of nodular protusions and small tumours that present many features of the brain lesions found in TSC 
patients40. Thus, it is tempting to propose that at least certain aspects of TSC, especially those related to 
aberrant migration, may involve superactivation of PAK2, rather than that of mTOR. Intriguingly, LKB1, 
a canonical upstream element in TSC1-TSC2-RHEB-mTOR signaling41, is well-established to regulate 
cell motility and axon growth42, and thus it is possible that TSC1-TSC2 complex-regulated PAK2 acti-
vation may be involved in the pathophysiological effects of this important tumour suppressor as well. 
Indeed, a correlation between increased PAK phosphorylation and biallelic LKB1 inactivation has been 
reported both in non-small cell lung cancer43 and breast cancer44. Thus, the observation that PAK2 acts 
as a mTOR-independent effector of TSC1-TSC2-RHEB signaling is not only highly novel, but it also fits 
well with the body of available biomedical literature.
Interestingly, the PAKs constitute a family of highly druggable kinases and many inhibitors, includ-
ing those that target PAK2, have been developed45. These compounds have yet to be tested in humans, 
but the relation between loss of functional TSC1/TSC2 and PAK2 hyperactivation makes it tempting 
to suggest that TSC could constitute a good candidate disease for such clinical trials. In any case, the 
Figure 4. Loss of Tsc2 results in Pak2 dependent wound healing defects. (A) Filamentous actin was 
visualised by performing rhodamin-phalloidin stainings. Wild-type MEFs are characterised by a relatively 
modest amount of filamentous actin and highly organised stess fibers (osf; an example is indicated in the 
figure). Loss of Tsc2 coincides with robust cytoskeletal rearrangements, including the formation of numerous 
lamellipodium-like networks (lln), increased and disorganised cytoskeletal actin, the appearance of 
prominent cortical actin structures (ca) and the formation of many small microspikes (μ s). Scale bars 20 μ m. 
(B) Scratch wound assays performed in Tsc2−/− and wild-type MEFs shows that Tsc2−/− cells migrate slower 
than wild-type MEFs. Reducing Pak2 by siRNA results in partial restoration of migration in Tsc2−/− MEFs, 
whereas control siRNA does not. (C) Quantification of the difference in lebesgue measure between the initial 
(0 hours) and final (24 hours) of the apparent scratch area confirms impaired migration in Tsc2−/− MEFs 
(p < 0.001) and restoration thereof by Pak2 siRNA (p = 0.0137). (D) Quantitative PCR results demonstrating 
that levels of Pak2 mRNA expression are not affected in Tsc2−/− MEFs, and are reduced upon siPAK2 
treatment, but not control siRNA (*< 0.0005).
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Figure 5. PAK2 phosphorylation levels are increased in brain lesions from TSC patients. (A) 
Immunohistochemistry data showing high levels of PAK2 autophosphorylation in giant cells of TSC 
patients (representative example of 5 patients). Scale Bars 1 cm; A, B: 80 μ M. (B) Double-staining in lesions 
from TSC patients shows co-localization of p-PAK2 and p-S6 in a significant fraction of the giant cells 
(representative immunohistochemistry analysis of 3 patients; same magnification used as in panel A).
Figure 6. Schematic representation of the TSC1-TSC2-RHEB network showing PAK2 as a new 
downstream target of RHEB. AML; angiomyolipoma, Mito; mitochondrion, GF; growth factor. Figure was 
designed by the authors, with no copyright owed elsewhere.
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current study has shown that the PAK2 kinase constitutes a bona fide mTOR-independent effector of the 
TSC1-TSC2 pathway and thus provides an important starting point for novel thinking on the develop-
ment of new therapeutic avenues for dealing with TSC.
Materials and Methods
Kinome array analysis. The protocol of the kinome array has been provided before in extensive 
detail46. Cell lysates were prepared with m-PER lysis buffer (Thermo-Scientific) containing protease 
(Roche) and phosphatase inhibitors (Thermo-Scientific). Protein quantification was done using Bradford 
analysis (Bio-Rad) and 100 μ g of protein was used for kinome analysis. After drying, the glass slides were 
exposed to a phosphor-imager plate for 72 hours and assessed with ScanAlyze software (http://rana.lbl.
gov/EisenSoftware.htm). Spot density and individual background intensities were analysed using grid 
tools and data from two individual experiments were exported to an excel sheet for further analysis. 
Individual results for each technical replicate were first subjected to Markov state analysis (i.e. is the 
peptide significantly more phosphorylated than background) and the number of reactions in which this 
is the case (an integer number between zero [in none of the 6 reactions significant radioactivity in incor-
porated into the substrate peptide] and six [in all 6 reactions significant radioactivity was incorporated 
into the substrate peptide]) is listed for each peptide for each of the experimental conditions (listed as 
Markov score). These Markov scores were collapsed on signal categories that provide insight into the 
difference in signaling between the Tsc2 proficient and deficient cells.
Expression vectors. pcDNA-Myc-Rheb was kindly provided by Liz Henske (Division of Pulmonary 
and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, U.S.A). 
pLKO.1-shRheb was generated in the Biomics Center of the Erasmus Medical Center (Rotterdam, The 
Netherlands) using the MISSIONtm shRNA library (Sigma-Aldrich). The shRheb targeting sequence 
is CCTCAGACATACTCCATAGAT. pGEX4T-PAK-Crib vector contains the RAC-binding domain of 
PAK2 and was cloned using BamHI and EcoRI restriction sites.
Cell culture and transfection. Tsc1−/−, Tsc2−/− and wild-type MEFs were kindly provided by David 
Kwiatkowski (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and 
Women’s Hospital, Boston, U.S.A). Rheb1−/− and wild-type MEFs were prepared as described before47. 
All MEFs were cultured in DMEM with high glucose content (Lonza), supplemented with 10% fetal 
calf serum (Sigma-Aldrich) and 1% penicillin/streptomycin (Gibco). Cells were cultured at 37oC and 
5% CO2. For transient transfection, 300. 000 cells were seeded in 6 well plates. Transfections were per-
formed 24 hours after seeding using Lipofectamine 2000 (Invitrogen). For the siRNA experiments, a 
SMARTpool: Accell siRNA specifically targeting Pak2 and a SMARTpool: Accell siRNA control were used 
(GE Healthcare, Dharmacon). Transfection was performed according to the manufacturers’ instructions 
24 hours after seeding.
Treatments, cell lysates, and Western blot analysis. Before lysis, cells were incubated for 2 hours 
in serum free medium, after which they were treated with rapamycin (1 h, 20 nM) and/or NSC23766 
(30 min, 20 μ M, Tocris Bioscience). Stimulations were terminated by an ice-cold phosphate buffered 
saline wash and cells were incubated with lysis buffer (m-PER containing protease and phosphatase 
inhibitors) for 30 minutes on ice. Cell lysates were collected by scraping and cleared by centrifugation 
at 14 000 rpm for 10 minutes in a pre-cooled (4 °C) centrifuge. Cell lysates were stored at − 80 °C before 
they were processed further for SDS-PAGE and immunoblotting. The following antibodies were used: 
TSC2 and actin (Santa Cruz Biotechnology); TSC1, MYC, p-PAK2, p-p70S6K and p-S6 (Cell Signaling); 
Rheb antibody was kindly provided by Richard Lamb (Department of Oncology, University of Alberta, 
Cross Cancer Institute, Edmonton, Alberta, Canada). Secondary antibodies used were IRDye 800CW 
Goat anti-Rabbit and IRDye 680RD Goat anti-Mouse (Li-Cor).
Pull-down assays. RAC activation48 was assessed using pull-down assays. Cells were lysed with 1X 
GST buffer (10% glycerol, 50 mM Tris-HCl pH7.4, 200 mM NaCl, 1% NP-40, 2 mM MgCl2, 1X protease 
inhibitors and 1X phosphatase inhibitors) and kept on ice. GST-PAK-Crib coupled beads were prepared 
by incubating GST-PAK-Crib with GST-beads (GE Healthcare) and 1X GST lysis buffer for 45 minutes 
at 4 °C. Beads were then washed 5 times with 1X GST buffer and incubated with 750 μ g of total protein 
lysate for 45 minutes at 4 °C on a rotating wheel. Samples were washed 3 times with 1X GST buffer and 
the beads were resuspended in 20 μ l Laemmli buffer followed by denaturation at 95 °C for 5 min. Samples 
were stored at − 80 °C before being processed by SDS-PAGE followed by western blot analysis.
Microscopy and image analysis. For immunofluorescence analysis49, cells were cultured on cover 
slips. Two percent paraformaldehyde (PFA) was used as a fixative and the cells were permeabilised with 
1% BSA and 0.1% Triton X-100 in PBS. Phalloidin-rhodamin (Santa Cruz Biotechnology) was added at 
a concentration of 1:200. Fluorescent images were made using a Leica (AOBS) microscope.
Migration Assays. Cells were plated in six-well plates and maintained in complete medium. Once 
the cells reached 80–90% confluence, a scratch was made in the center of the cell monolayer using a 
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sterile plastic pipette tip. Cells were washed immediately with PBS to remove floating cellular debris 
and incubated for an additional 24 hours. The ability of the cells to migrate into the scratch area was 
assessed in standard growth conditions after 24 hours by comparing the 0- and 24-hour phase-contrast 
micrographs of six marked points along the scratched area on each plate. The total remaining scratch 
area was determined using ImageJ software (Rasband, W.S., ImageJ, U.S. National Institutes of Health, 
Bethesda, Maryland, USA). Results are presented as the difference percentage of each time point. For 
the siRNA experiments, the scratch was made 72 hours after transfection, and cells were analysed as 
described above.
RNA extraction and RT-PCR. RNA extraction was performed using a RNA extraction kit (Qiagen) 
according to the manufacturers’ instructions. 500 ng of RNA was used as template for cDNA preparation 
with the iScript cDNA Synthesis Kit (Bio-Rad). Quantitative PCR was performed in a IQ5 cycler PCR 
machine (Bio-Rad), using the Kapa SYBR Fast qPCR kit (Kapa Biosystems). Primers used are described 
in Supplementary table 1. Expression levels were corrected for expression of two house-keeping genes, 
Actb and Gapdh, averaged and presented as fold changes.
Tissue preparation and immunohistochemistry. Immunohistochemistry was performed on tis-
sue samples from five TSC patients (M/F: 3/2; TSC1/TSC2: 1/4). All patients included in this study 
fulfilled the diagnostic criteria for TSC50 and were obtained from the archives of the Departments of 
Neuropathology of the Academic Medical Center (University of Amsterdam) and the University Medical 
Center Utrecht (UMCU). Tissue was obtained in accordance with the Declaration of Helsinki and the 
Academic Medical Center (AMC) Research Code.
Tissue was fixed in 10% buffered formalin and embedded in paraffin. Paraffin-embedded tissue was 
sectioned at 6 μ m, mounted on organosilane-coated slides (Sigma, St. Louis, MO) and used for immuno-
histochemical staining. Paraffin-embedded sections were deparaffinized, re-hydrated, and incubated for 
20 min in 0.3% H2O2 diluted in methanol to quench endogenous peroxidase activity. Antigen retrieval 
was performed by incubation for 10 min at 121 °C in citrate buffer (0.01 M, pH 6.0). Sections were 
washed with PBS and incubated for 30 min in 10% normal goat serum (Harlan Sera-Lab). Incubation 
with anti p-PAK2 antibody (Cell Signalling, 1:50) was done overnight at 4 °C. Thereafter, sections were 
washed in PBS and stained with ready-to-use Powervision peroxidase system (Immunologic) and 
3,3′ -diaminobenzidine (DAB; Sigma) as chromogen. Sections were counterstained with haematoxylin, 
dehydrated and coverslipped.
For double-labeling, after incubation with p-PAK2 antibody, sections were incubated with Brightvision 
poly-alkaline phosphatase (AP)-anti-Rabbit (Immunologic) for 30 minutes at room temperature. Sections 
were washed with PBS and the pH was adjusted with Tris-HCl buffer (0,1 M; pH 8,2). AP activity was 
visualized with the AP substrate kit I Vector Red (SK-5100, Vector laboratories Inc.). Sections were then 
incubated at 121 °C in citrate buffer (10 mM NaCi, pH 6.0) for 10 minutes, in order to remove the first 
primary antibody. Incubation with the second primary antibody (p-S6, Cell Signaling Technology, 1:50) 
was performed overnight at 4 °C. AP activity was visualized with the AP substrate kit III Vector Blue 
(SK-5300, Vector laboratories). Controls performed with depletion of the primary antibody showed no 
staining in any of the material tested (data not shown).
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